Effects of recombinant human growth hormone on donor-site healing in severely burned children.

Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL

Annals of surgery1 Oct 1990Cited by 214 (Europe PMC)

PMID2121109DOI10.1097/00000658-199010000-00005PepBankPUB-02121109

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In severely burned children, rHGH increased serum IGF-1 versus placebo (4.8 versus 1.6 U/mL, p less than 0.05).
In plain wordsIn severely burned children, rHGH increased serum IGF-1 versus placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum IGF-1
Study
n: not reported in source
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.2 mg/kg/day · from admission throughout hospitalizationAs given in this study (human).
Measurements
IGF-1
4.8 U/mL
rHGH
IGF-1
1.6 U/mL
placebo
Source sentences
Summary
Patients receiving 0.2 mg/kg/day rHGH demonstrated significantly higher serum IGF-1 levels at 4.8 +/- 1.7 U/mL compared to placebos at 1.6 +/- 0.4 U/mL (p less than 0.05) and a significant decrease in donor-site healing times compared to placebo (p less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty patients who were 2 to 18 years old, with 40% or more total body surface area (TBSA) and 20% or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study
Report a problemFND-0212110901
02HumanRandomized controlled trialEfficacy outcome
In severely burned children, rHGH significantly reduced donor-site healing time versus placebo.
In plain wordsIn severely burned children, rHGH reduced donor-site healing time versus placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseDonor-site healing time
Study
n: not reported in source
Comparator
Placebo
Outcome group
Wound healing · Skin and wound
Studied dose
0.2 mg/kg/day · from admission throughout hospitalizationAs given in this study (human).
Source sentences
Summary
Patients receiving 0.2 mg/kg/day rHGH demonstrated significantly higher serum IGF-1 levels at 4.8 +/- 1.7 U/mL compared to placebos at 1.6 +/- 0.4 U/mL (p less than 0.05) and a significant decrease in donor-site healing times compared to placebo (p less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty patients who were 2 to 18 years old, with 40% or more total body surface area (TBSA) and 20% or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study
Report a problemFND-0212110902
03HumanRandomized controlled trialEfficacy outcome
In severely burned children, rHGH reduced hospital stay from 0.80 to 0.54 days/%TBSA versus placebo (p less than 0.05).
In plain wordsIn severely burned children, rHGH reduced hospital stay versus placebo.
Peptide
HGH (somatotropin)
Outcome
DecreaseHospital stay per burned surface area
Study
n: not reported in source
Comparator
Placebo
Outcome group
Intensive care and hospital outcomes · Whole body
Studied dose
0.2 mg/kg/day · from admission throughout hospitalizationAs given in this study (human).
Measurements
LOS/%TBSA
0.8 days/%TBSA
placebo
LOS/%TBSA
0.54 days/%TBSA
rHGH
Source sentences
Summary
Length of hospital stay (LOS/%TBSA) was decreased from 0.80 +/- 0.10 days/%TBSA burned in the placebo group to 0.54 +/- 0.04 days/%TBSA burned in the 0.2 mg/kg/day treatment group (p less than 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This translates, for the average 60% TBSA burned patient, to a decrease in LOS from 46 to 32 days.
Summary · context
Forty patients who were 2 to 18 years old, with 40% or more total body surface area (TBSA) and 20% or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study
Report a problemFND-0212110903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.